Compass Therapeutics, Inc. (CMPX): R&D Expense
$55.97M
Year ended 2025-12-31
$59.46M
Trailing 12 months to 2026-06-30
+23.1%
3-year compound annual growth
+30.3%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $55.97M | +32.2% | 2026-03-05, From 2025-01-01 |
| 2024-12-31 | $42.34M | +11.1% | 2026-03-05, From 2024-01-01 |
| 2023-12-31 | $38.12M | +27.1% | 2025-02-27, From 2023-01-01 |
| 2022-12-31 | $30.00M | +47.5% | 2024-03-21, From 2022-01-01 |
| 2021-12-31 | $20.34M | +36.5% | 2023-03-15, From 2021-01-01 |
| 2020-12-31 | $14.90M | -33.6% | 2022-03-18, From 2020-01-01 |
| 2019-12-31 | $22.45M | n/a | 2021-03-05, From 2019-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | 2025-12-31 | $55.97M | +32.2% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $201.58M | +171.6% |
| Amgen Inc (AMGN) | 2025-12-31 | $7.27B | +21.9% |
| Repligen Corp (RGEN) | 2025-12-31 | $54.18M | +25.4% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $9.08M | +33.1% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $94.77M | -4.8% |
| Biogen Inc. (BIIB) | 2025-12-31 | $1.78B | -10.2% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $17.73M | +42.2% |
| Gilead Sciences, Inc. (GILD) | 2025-12-31 | $5.80B | -1.8% |
Compare CMPX, VXRT, AMGN, RGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗